Zenapax daclizumab: Phase II; marketed to prevent acute organ rejection following renal transplant

Zenapax showed efficacy in a trial of 43 allogeneic bone marrow transplant recipients. The first 24 patients received 1 mg/kg Zenapax on days 1, 8, 15, 22 and 29. Among these patients, 29 percent had ...